In cancer, Survivin can be degraded by a variety of mechanisms, such as amplification of Survivin sites on chromosome 17q25 [18], demethylation of Survivin exons [9], increased promoter activity [10], and upstream activation of PI3K/AKT or MAPK signaling pathways [11]. This evidence concerns the gene AKT1 and cancer.